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Background: Peptide receptor radionuclide therapy (PRRT) with 177Lu-[DOTA0,Tyr3]octreotate (177Lu-octreotate) is
generally performed using a fixed activity of 7.4 GBq (200 mCi) per course bound to 180 to 300 μg of the peptide.
While this single activity may lead to suboptimal radiation doses in neuroendocrine tumors (NET) with advanced or
bulky disease, dose escalation has been withheld due to concerns on potential tumor somatostatin receptor
saturation with reduced efficacy of the added activity. In vivo saturation effects during standard-dose PRRT based
on quantification of pre- and intra-therapeutic 68Ga-DOTATOC positron emission tomography (PET) imaging might
guide potential dose escalation.
Methods: Five patients with metastatic NET of the pancreas underwent 68Ga-DOTATOC PET/CT before and directly
after standard-dose PRRT with 177Lu-octreotate. In each patient, four target tumor lesions, normal liver parenchyma,
and the spleen were evaluated and the ratios of SUVmax of the target lesions to liver (SUVT/L) and spleen (SUVT/S)
were calculated; paired Student's t test was performed with p < 0.05 for pre-/intra-PRRT comparisons.
Results: The mean intra-therapeutic tumor SUVmax showed no significant change (per-lesion paired t test) compared
to pretreatment values (−9.1%, p = 0.226). In contrast, the SUVmax of the normal liver parenchyma and spleen were
significantly lower directly after infusion of 7.4 GBq 177Lu-octreotate. Consequently, SUVT/L and SUVT/S increased
significantly from pretreatment to intra-therapeutic examination: SUVT/L (p < 0.001) from 2.8 ± 1.3 (1.3 to 5.8) to 4.7 ± 3.0
(2.1 to 12.7) and SUVT/S (p < 0.001) from 1.2 ± 0.7 (0.4 to 3.0) to 3.5 ± 1.5 (1.6 to 7.9).
Conclusions: This small retrospective study provides preliminary evidence for the absence of relevant in vivo saturation
of somatostatin receptor subtype 2 (sst2) in tumor lesions during PRRT with standard activities of 177Lu-octreotate in
contrast to normal tissue (liver, spleen) showing limited receptor capacity. After being confirmed by larger series, this
observation will have significant implications for PRRT: (1) Higher activities of 177Lu-octreotate might be considered
feasible in patients with high tumor disease burden or clinical need for remission, and (2) striving to reduce the
amount of peptide used in standard preparations of 177Lu-octreotate appears futile.* Correspondence: samer.ezziddin@ukb.uni-bonn.de
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Neuroendocrine tumors (NET) commonly overexpress
somatostatin receptors, in particular the subtype 2 (sst2),
which are targeted for tumor-directed imaging and the-
rapy [1-4]. 68Ga-labeled somatostatin analogues with high
affinity to sst2 such as 68Ga-DOTA-D-Phe1-Tyr3-octreotate
or 68Ga-DOTA-D-Phe1-Tyr3-octreotide are widely used
for positron emission tomography (PET) imaging of
NET [5-7]. The same sst2 ligands coupled to β-emitters
90Y or 177Lu are successfully utilized for targeted radio-
nuclide therapy, peptide receptor radionuclide therapy
(PRRT) comprising a well-established, effective systemic
treatment modality in patients with inoperable, meta-
static gastroenteropancreatic NET (GEP NET) [8-11].
Standard PRRT with 177Lu-[DOTA0,Tyr3]octreotate
(177Lu-octreotate) is performed with administration of a
fixed activity of 7.4 GBq (200 mCi) per course [12-15].
This amount of activity is usually bound to 180 to 300 μg
of the peptide with the chelator DOTA, [DOTA0,Tyr3]
octreotate. One argument against dose escalation has been
the concern on receptor saturation effects in the tumor le-
sions leading to reduced uptake and efficacy of the added
activity [12,16-18]. This assumption has left PRRT with
177Lu-octreotate with an upper limit of activity per cycle
of 7.4 GBq that until date has not been challenged; to the
best of our knowledge, there are no reports of treatment
with higher activities. However, it can be expected that
this will lead to suboptimal treatment in some patients
with more advanced/bulky tumor disease and a clinical
need for tumor remission. The objective of this retrospec-
tive study was to investigate potential in vivo saturation of
somatostatin receptors observed during standard PRRT
according to quantification of intra-treatment PET studies.
Methods
Patients
The local committee on ethics approved this retrospective
study, and all subjects had provided prior written informed
consent. Pre- and post-treatment 68Ga-DOTATOC PET/
CT images of five patients (three women and two men;
age range, 47 to 79 years) with histologically confirmed,
unresectable, metastatic NET of the pancreas (P-NET)
who underwent one cycle of PRRT with 177Lu-octreotate
between 2011 and 2012 were studied. All patients fulfilled
the general inclusion criteria for PRRT including sufficient
tumor uptake (i.e., ≥normal liver uptake) on baseline re-
ceptor imaging (68Ga-DOTATOC PET/CT) [19-21].
PRRT
PRRT was performed with 7.4 GBq (200 mCi) 177Lu-
octreotate administered in 30 min according to the stan-
dard protocol from Rotterdam. The 177Lu (IDB Holland,
Baarle-Nassau, Netherlands) had a specific activity in the
approximate range of 100 to 160 GBq/μmol at the time ofadministration. The peptide labeling [22,23] was per-
formed such that an apparent specific activity of about 54
GBq/μmol (ratio of activity to the total amount of peptide)
was obtained. Positively charged amino acids were coad-
ministered for nephroprotection [12,24] (lysine 2.5% and
arginine 2.5% in 1 L 0.9% NaCl; infusion of 250 mL/h).
Somatostatin receptor PET imaging
DOTATOC was labeled with 68Ga eluted from an in-
house 68Ge/68Ga generator following the procedure des-
cribed by Zhernosekov et al. [25]. All patients underwent
pretreatment as well as intra-therapeutic 68Ga-DOTATOC
PET/CT: Pretreatment PET/CT was performed 1 to 3 days
before PRRT and intra-therapeutic PET/CT during PRRT,
with PET tracer injection 30 min after the start of the
treatment infusion. To minimize the interfering effects of
the time lag between treatment administration and PET
tracer injection on quantitative analysis of intra-thera-
peutic images, 68Ga-DOTATOC was injected on the treat-
ment ward without delay; the time interval between the
end of 177Lu-octreotate infusion and 68Ga-DOTATOC
injection for intra-therapeutic PET was <1 min. The scans
were acquired from the base of the skull to the upper
thighs (five to seven bed positions) 30 min after the injec-
tion of 200 MBq 68Ga-DOTATOC. The hybrid PET/CT
scanner (Biograph 2, Siemens Medical Solutions Inc.,
Hoffman Estates, IL, USA) consisted of a dual-detector
helical CT and a high-resolution PET scanner with a
16.2-cm axial field of view and a lutetium oxyorthosi-
licate (LSO) crystal detector (6.45 × 6.45 × 25 mm). CT
was performed for attenuation correction and anato-
mical localization using the following parameters: 60
mAs, 130 kV, 0.8 s/tube rotation, slice thickness 5 mm,
slice width 5 mm, and table feed 8 mm/s. Immediately
following the CT image acquisition, PET data were ac-
quired for 5 min per bed position. The coincidence time
resolution was 500 ps with a coincidence window of 4.5 ns.
The sensitivity was 5.7 cps/kBq at 400 keV. The attenua-
tion-corrected PET data were reconstructed using a
standardized ordered-subset expectation maximization
(OSEM) iterative reconstruction with two iterations and
eight subsets and a 5-mm Gaussian filter.
Image analysis and statistical methods
The standardized uptake value (SUV) was determined as
a measure of DOTATOC uptake. In each patient, three
liver metastases with unimpaired delineation from other
sources of tracer accumulation along with the primary
tumor or an extrahepatic metastasis if the primary was
resected were selected as target lesions, and normal liver
parenchyma as well as the spleen (if not affected by
tumor infiltration) as background control. Irregular re-
gions of interest with a threshold of 50% of the SUVmax
were drawn and the respective SUVs were recorded. In
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the target lesions to maximal hepatic uptake (SUVT/L)
and maximal splenic uptake (SUVT/S) were calculated
in pre- and post-treatment 68Ga-DOTATOC PET/CT
images. Paired Student's t test was performed with a
significance level of p < 0.05 to examine the changes in
receptor status after administration of 177Lu-octreotate.
The statistical software package SPSS (version 20, SPSS
Inc., Chicago, IL, USA) was used to analyze the data.Results
In each of the five patients, four target tumor lesions, one
normal liver region, and the spleen were evaluated. The
mean SUVmax before therapeutic administration of
177Lu-
octreotate was 22.5 ± 8.5 (range, 9.7 to 38.0) in the tumor
lesions, 8.5 ± 2.5 (range, 6.5 to 11.6) in the normal liver
parenchyma, and 21.4 ± 8.9 (range 11.4 to 31.7) in the
spleen (Table 1). The highest intra-individual variation of
SUVmax in the tumor lesions at baseline was 8.8 ± 5.7
(range 2.6 to 15.9).
Directly after therapeutic infusion of 7.4 GBq 177Lu-
octreotate, the mean ‘intra-therapeutic’ tumor SUVmax of
injected 68Ga-DOTATOC was 20.0 ± 10.4 (range, 7.6 to
50.7), showing no significant change on per-lesion com-
parison (−9.1%; paired t test, p = 0.226). In contrast, the
intra-therapeutic SUVmax of the normal liver parenchyma
(4.8 ± 2.0; range, 2.3 to 7.5) and the spleen (5.6 ± 0.8;
range, 4.7 to 6.4) were significantly lower compared to
pretreatment values (p = 0.016 and p = 0.015, respectively).
Consequently, the tumor-to-nontumor ratios (SUVT/L
and SUVT/S) increased significantly from pretreatment
to intra-therapeutic assessment: SUVT/L (p < 0.001) from
2.8 ± 1.3 (1.3 to 5.8) to 4.7 ± 3.0 (2.1 to 12.7) and SUVT/S
(p < 0.001) from 1.2 ± 0.7 (0.4 to 3.0) to 3.5 ± 1.5 (1.6 to
7.9). Figures 1 and 2 illustrate the mean change of SUVT/L
and SUVT/S in each patient and in a sample patient,
respectively.Table 1 SUV parameters of 68Ga-DOTATOC PET imaging
before and directly after administration of PRRT with
7.4 GBq 177Lu-octreotate
SUVmax (mean ± SD) p
valueaPretreatment Intra-therapeutic
Tumor lesions 22.5 ± 8.5 20.0 ± 10.4 0.226
Normal liver 8.5 ± 2.5 4.8 ± 2.0 0.016
Spleen 21.4 ± 8.9 5.6 ± 0.8 0.015
SUV ratio
Tumor-to-liver 2.8 ± 1.3 4.7 ± 3.0 <0.001
Tumor-to-spleen 1.2 ± 0.7 3.5 ± 1.5 <0.001
aPaired t test.Discussion
This small retrospective study with 20 analyzed tumor
lesions in five patients provides preliminary evidence for
the absence of relevant in vivo receptor saturation effects
regarding the targeted sst2 receptors in tumor lesions
during PRRT with standard activities of 177Lu-octreotate.
This observation is contrasted by highly significant satu-
ration effects in normal (nontumor) tissue depicted by
somatostatin receptor PET imaging.
Binding of labeled or unlabeled somatostatin analogues
to the highly overexpressed membranous sst2 in NET
triggers a fast and efficient internalization process of the
ligand-receptor complex within 2.5 min [26]. In nuclear
medicine, this mechanism results in very effective accu-
mulation of intra-cellular radiolabeled peptides and per-
mits successful tumor imaging and targeted radionuclide
therapy [27-29]. The ‘recycling’ process of the internalized
receptors to the plasma membrane is, on the other hand,
relatively slow and may take several hours [26]. This
results in saturation-like effects whenever infusion of
radiolabeled sst2 ligands is preceded by application of
labeled or unlabeled ligands and limits the amount of
radiolabeled molecules and thus activity to be delivered
into the tumor. The 68Ga-DOTATOC uptake in intra-
therapeutic PET imaging directly after 177Lu-octreotate
administration, i.e., 30 min after the beginning of the
radiopeptide infusion, is mediated by the ‘unsaturated’
membranous sst2 binding the PET tracer compound;
the extent of its uptake is probably not influenced by
(if at all present) recently recycled receptors after 177Lu-
octreotate infusion. This imaging approach may allow
effective in vivo quantification of the (unbound and avail-
able) membranous receptor density during PRRT.
Few studies have reported the possible positive effects
associated with the presence of high peptide amounts on
the uptake of radiolabeled somatostatin analogues in
tumor tissues [28,30-32]. A systematic investigation of the
impact of peptide mass on the uptake of 68Ga-DOTATOC
in NET revealed a saturable tracer accumulation in nor-
mal organs (spleen and liver) after the administration of
50 μg of unlabeled octreotide [31]. In contrast to this, a
saturation effect in the tumor tissue was observed only
after preloading with considerably higher amounts of
unlabeled octreotide (250 or 500 μg). The increase of
selective uptake in tumor lesions after injection of 50 μg
octreotide in the same study moreover indicated potential
up-regulation of tumor somatostatin receptor density by
unlabeled octreotide [31]. Similar results have been ob-
served after administration of long-acting somatostatin
14.5 to 11.4 days prior to PET/CT examination [30]. To
date, however, radionuclides with high specific activity and
relatively low amounts of peptide are suggested for the
purpose of PRRT. Consequently, treatment with 177Lu-
octreotate is performed with up to 7.4 GBq 177Lu-
Figure 1 SUV ratios of target lesions to normal tissue in pre- and intra-therapeutic settings using 68Ga-DOTATOC PET. The images show
the comparison of the mean tumor-to-liver (A) and tumor-to-spleen (B) SUV ratios in each patient (n = 5).
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statin saturation in tumor lesions. The results of our study
confirm the absence of relevant receptor saturation in
tumor lesions, while at the same time demonstrating a
striking saturation in the spleen and liver, during standard
treatment with 7.4 GBq 177Lu-octreotate; this finding may
encourage dose escalation strategies, such as in patients
with higher tumor disease burden.
Application of different somatostatin analogues, octreo-
tide (68Ga-DOTATOC) and octreotate (177Lu-[DOTA0,
Tyr3]octreotate), for imaging and treatment may be
regarded as one limitation in this study. Considering theFigure 2 Pretreatment (above) and intra-therapeutic (below) 68Ga-DO
metastases of a P-NET (tail of the pancreas) and high hepatic tumor diseas
(SUVT/L and SUVT/S) after
177Lu-octreotate administration (+111.4% and +14predominant affinity of these somatostatin analogues
for the same receptor subtype, the sst2, the receptor
‘saturation’ after treatment with 177Lu-octreotate may very
well be determined using 68Ga-DOTATOC PET. The
SUVmax values are in line with reported results of other
authors on 68Ga-DOTATOC PET [33,34]. The main limi-
tation of our study is the small population size (n = 5),
which obviously restricts the strength of our conclusions.
However, the striking and highly significant increase of
tumor-to-background ratios of 68Ga-DOTATOC uptake
(SUVT/L and SUVT/S) after
177Lu-octreotate administra-
tion with no significant change in the uptake intensity ofTATOC PET/CT images of a patient. The patient has liver and bone
e burden. The significant increase of tumor-to-nontumor SUV ratios
2.2%, respectively, both p < 0.001) is visible on the images.
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of normal tissues with at the same time preserved receptor
capacity of tumor lesions during standard treatment with
7.4 GBq 177Lu-octreotate.
Conclusions
Derived from a small series of intra-individual comparison
of pre- and intra-therapeutic somatostatin receptor PET
imaging, there is no evidence for clinically relevant soma-
tostatin receptor saturation of targeted tumor lesions. For
PRRT with standard activities, the tumor receptor capacity
of sst2 does not seem to be nearly reached in contrast to
the obviously limited receptor-mediated radiopeptide up-
take capacity of normal tissue such as the liver and spleen.
After being confirmed by larger series, this observation
may have important implications for PRRT, in that
(1) higher activities of 177Lu-octreotate (>7.4 GBq) might
be considered whenever high tumor disease burden or
clinical need for remission exceeds toxicity issues and
(2) the amount of peptide used in standard preparations
of 177Lu-octreotate is viewed as uncritical, i.e. attempts to
reduce peptide mass by employing 177Lu of ultrahigh spe-
cific activity would appear nonbeneficial.
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